Digital Content 
NEWS #PharmaBuzz
30 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor-302569442.html
20 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tremfya-guselkumab-achieves-us-approval-for-subcutaneous-induction-in-adults-with-ulcerative-colitis-now-the-first-and-only-il-23-inhibitor-with-a-fully-subcutaneous-regimen-302561993.html
19 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/19/3153234/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-subcutaneous-induction-regimen-in-ulcerative-colitis-a-first-for-an-IL-23-inhibitor.html
02 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250902492755/en/Polpharma-Biologics-and-MS-Pharma-Sign-Licensing-Agreements-for-Proposed-Vedolizumab-PB016-Ocrelizumab-PB018-and-Guselkumab-PB019-Biosimilars
29 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/johnson--johnson-files-with-us-fda-to-include-new-evidence-in-tremfya-guselkumab-label-as-the-only-il-23-inhibitor-to-demonstrate-significant-inhibition-of-joint-structural-damage-in-active-psoriatic-arthritis-302516055.html
11 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-data-show-tremfya-guselkumab-is-the-only-il-23-inhibitor-proven-to-significantly-inhibit-progression-of-joint-structural-damage-in-active-psoriatic-arthritis-302475588.html
Share 